CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$3.86 USD
+0.40 (11.68%)
Updated May 31, 2024 03:59 PM ET
After-Market: $3.86 0.00 (-0.10%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth A Momentum D VGM
Brokerage Reports
0 items in cart
CASI Pharmaceuticals Inc. [CASI]
Reports for Purchase
Showing records 61 - 70 ( 70 total )
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Phase 2 Studies On Track; Evomela US Approval Boosts China Application; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
ENMD-2076 Studies Moving Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Developing Niche Therapies for the Largest Oncology Markets; Assuming Coverage With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
2Q15 Update; Looking Forward to Top-Line Phase 2 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIN C
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Advancing to POC Trials in Multiple Indications; Initiating with Buy and a PT of $2.50
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: LIN C
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G